Pediatrics Doctors in Colonial Heights, VA Accepting Medicare

8 Pediatrics doctors found. Showing 1 - 8

Ruby R Tan, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 301 Jennick Dr # A, Colonial Heights, VA 23834 Phone: 804-524-0055

Dr. Amabel C Viniegra-sibal, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 301 Jennick Dr, Suite A, Colonial Heights, VA 23834 Phone: 804-524-0055    Fax: 804-524-0069

Sunita Talegaonkar, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 430 Clairmont Ct, Suite 211, Colonial Heights, VA 23834 Phone: 804-526-0346    Fax: 804-526-7675

Skye Lu, DO Pediatrics Medicare: Medicare Enrolled Practice Location: 325 Charles H Dimmock Pkwy Ste 600, Colonial Heights, VA 23834 Phone: 804-518-3288    Fax: 888-990-1241

Brian Mark Schenberg, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 210 Temple Ave, Colonial Heights, VA 23834 Phone: 804-520-6137    Fax: 804-520-7394

David Michael Zlotkin, M.D. Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 1260 Temple Ave, Colonial Heights, VA 23834 Phone: 804-518-2597

Aida Ong Obusan, MD,FAAP Pediatrics - Adolescent Medicine Medicare: Not Enrolled in Medicare Practice Location: 325 Charles H Dimmock Pkwy, Suite 600, Colonial Heights, VA 23834 Phone: 804-518-3288

Rolanda Ann Mcdonald-johnson, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 430 Claremont Ct, Suite 211, Colonial Heights, VA 23834 Phone: 804-526-0346    Fax: 804-526-7675

News Archive

Physical activity associated with lower risk of death for prostate cancer patients: Study

A new study of men with prostate cancer finds that physical activity is associated with a lower risk of overall mortality and of death due to prostate cancer. The Harvard School of Public Health and University of California, San Francisco researchers also found that men who did more vigorous activity had the lowest risk of dying from the disease.

Reviva announces successful completion of End-of-Phase 2 meeting for RP5063 drug

Reviva Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the discovery and development of new, safer and highly effective therapies for chronic indications, announced today the successful completion of an End-of-Phase 2 meeting with the Food and Drug Administration for its lead, new investigational antipsychotic drug, RP5063.

MPP cell population: A new potential target for treating infections and allergies

Millions of people in both the developing and developed world may benefit from new immune-system research findings from the University of Pennsylvania School of Veterinary Medicine.

KMI receives $2.8M grant to support delivery of teletherapy service to stroke survivors in rural areas

Kinetic Muscles, Inc., an innovator in robotic neurotherapy technology, today announced it has received a $2.8 million grant from the National Institute of Neurological Disorder and Stroke of the National Institutes of Health that will support delivery of KMI's revolutionary teletherapy service to stroke survivors in rural areas.

Pivotal Therapeutics enrolls first patient in POMEGA Phase IIa clinical trial of PVT-100

Pivotal Therapeutics Inc., a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced today the enrollment of the first patient in Pivotal's POMEGA Phase IIa clinical trial with PVT-100.

Read more Medical News

› Verified 2 days ago